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Abstract 
Infection diseases (ID) have existed for a long time provoking many people’s death throughout human 
history. They were recognised as infectious in early epidemics but, due to lack of knowledge, the true 
epidemiology of disease and the efforts to control them failed. Only in the XV century the fact that these 
infections were transmitted by air began to be considered and only in the XX century the antibiotics 
were created. In the XIX century Sammelweiss documented the first healthcare-associated infection 
(HAI) demonstrating that IDs could be acquired in medical facilities.  
This work is about the impact of these infections in Mainland Portugal and the quantification of its 
burden of disease. It is composed of two studies. The first is based on Cassini et al. [1] and measures 
the burden of disease of some important HAIs using the disability-adjusted life years (DALY). The 
second estimates the costs of the same infections in the public hospitals of Mainland Portugal.  
In 2016, healthcare-associated urinary tract infection (UTI) was the HAI with the highest number of 
cases (3679) and DALYs (39,322, representing 33.64% of the total DALYs). It is also the infection with 
the largest DALY per 100,000 inhabitants (4,448 per 100,000). Surgical site infection (SSI) had the 
lowest number of DALYs (1,033) and the lowest DALY per 100,000 general population (117 DALYs 
per 100,000 inhabitants).  
The total estimated costs for Portugal were around 33 million of euros. UTI was the most expensive 
HAI corresponding to 10.93€ million, while healthcare-associated Clostridium difficile infection (CDI) 
was the cheapest corresponding to 0.79€ million. Considering the average cost by admission with HAI, 
Neo is the one that costs more to the Portuguese healthcare system (SNS, Sistema Nacional de Saúde), 
4,091.69€. 
This work is the first one that uses national data and innovator techniques to estimate the burden and 
costs of HAI in Portugal. Comparing with other studies in Europe the number of DALYs per admission 
is higher in Mainland Portugal. Nonetheless, this increased level is aligned with the European Centre 
for Disease Prevention and Control (ECDC) evidence where Portugal presents one of the highest rates 
of HAIs in the European Union and European Economic Area (EU/EEA). When comparing the average 
costs with other countries like France, United Kingdom or United States, the costs of most of these 
countries are lower, because the prevalence of HAIs in Portugal is higher than in the other countries.  
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Resumo 
As doenças infecciosas (DI) existem há muito tempo provocando a morte de muitas pessoas ao longo 
da história do ser humano. Estas foram reconhecidas como infecciosas nas primeiras epidemias, mas 
devido à falta de conhecimento da verdadeira epidemiologia da doença, os esforços para as controlar 
falharam. Apenas no século XV é que o facto de estas infeções serem transmitidas pelo ar foi 
considerado e apenas no século XX é que os antibióticos foram inventados. No século XIX 
Sammelweiss documentou a primeira infeção associada aos cuidados de saúde (HAI, Healthcare-
Associated Infection) mostrando que as DI podiam ser adquiridas em instalações médicas. 
As HAI são infeções adquiridas pelos utentes quando internados em hospitais ou em lares, sendo 
responsáveis por milhares de mortes e de elevados custos para os países [2–4], onde Portugal é um dos 
países com maior incidência de HAI na UE [5]. São, portanto, um problema para a saúde pública e para 
os diferentes sistemas de saúde tendo de ser vigiados e controlados. 
Para esta finalidade é necessário estudar a carga da doença, ou seja, o estudo do impacto de uma ou 
várias doenças numa população ou região geográfica usando vários indicadores (mortalidade, 
deficiências associadas, custos, entre outros). Neste trabalho foram considerados os DALY (Disability-
Adjusted Life Years) e os custos para medir a carga da doença. Foram, também, consideradas 6 HAI 
para estudo, por serem as mais comuns, pneumonia (P), infeção primária da corrente sanguínea (BSI), 
sepsis neonatal (Neo), infeções do trato urinário (UTI), infeção do local cirúrgico (SSI) e infeção por 
clostridium difficile (CDI, bactéria presente na flora intestinal) presentes nos hospitais públicos de 
Portugal Continental, no ano de 2016. 
Este trabalho está dividido em dois artigos: o primeiro working paper, baseado em Cassini et al. [1], 
submetido ao “The Journal of Hospital Infection”, mede a carga da doença de algumas HAI usando os 
DALY. O segundo working paper, submetido à “Acta Médica Portuguesa”, estima os custos das mesmas 
infeções nos hospitais públicos de Portugal Continental.   
Os DALY são o número de anos de vida saudáveis que uma pessoa perde devido a morte prematura ou 
a sequelas devido a uma ou várias doenças. Dividem-se, portanto, em duas componentes, o número de 
anos de vida devido a morte prematura (YLL) e os anos perdidos devido a doença (YLD). Sendo que o 
seu cálculo se traduz por: DALY=YLD+YLL. 
Em 2016, a UTI foi a HAI com o maior número de casos, enquanto a CDI é a que teve menos casos, 
não contando com a Neo, pois esta só afeta recém-nascidos até um 1 ano de idade. A faixa etária dos 80 
aos 108 é a que tem maior incidência, excluindo os casos de Neo (40.19% do total) e o número de 
admissões aumenta ao longo da idade, principalmente a partir dos 50 anos.  
 Em termos de carga da doença a UTI e a P foram as HAI com maior carga com 39.322 DALY e 31,242 
DALY, respetivamente, (representando 33,64% e 26.72% dos DALY totais). A SSI foi a que teve uma 
carga menor, 1033 DALY, porque a maioria dos SSI não implicarem uma admissão no hospital e apenas 
as SSI severas terem sido registadas na base de dados em estudo. Estes resultados contrariam Cassini et 
al. [1], onde este coloca a P como a HAI com maior carga da doença. Em contrapartida, são suportados 
por Jon Otter [6] que também coloca a UTI no top das HAI com mais DALY no mundo.   
A infeção com o maior número de DALY por 100.000 habitantes (4.448 por 100.000) é, também, a UTI. 
O número de DALY por 100.000 bastante superior em Portugal (13.225 em 100.000) comparando com 
o Cassini et al [1] para a UE/EEA (501 em 100.000). Isto ocorre por três motivos: primeiro, não é 
possível obter o número direto de HAI na base de dados de Morbilidade Hospitalar (utilizou-se os pesos 
das HAI nos resultados do inquérito do ECDC de 2017 para estimar as HAI portuguesas). Segundo, a 
taxa de infeção em Portugal é mais alta do que na EU. Terceiro, este estudo usa o total da população de 
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Portugal Continental, enquanto Cassini et al [1] utiliza amostras de hospitais na UE/EEA, onde em 
alguns países foram contabilizados poucos hospitais.  
As BSI foi a HAI com o maior número de DALY por admissão, porque o quociente entre o número de 
DALY da BSI e o número de admissões não é proporcional ao número de DALY da BSI com o número 
de habitantes. Ou seja, o número de habitantes é superior ao número de admissões levando a resultados 
diferentes.  
Os custos totais estimados para Portugal foram cerca de 33 milhões de euros, sendo que a faixa etária 
dos 80 aos 108 anos custa cerca de 12 milhões de euros (36.68%) e os indivíduos com menos do que 18 
anos são os mais baratos (7.12%). A UTI foi a HAI mais dispendiosa correspondendo a 10,93 milhões 
de euros, enquanto a infeção clostridium difficile (CDI) foi a menos dispendiosa correspondendo a 0,79 
milhões de euros.  
Considerando o custo médio por admissão com HAI, a infeção neonatal por sepsis (Neo) foi aquela que 
mais custou ao Sistema Nacional de Saúde (SNS), 4.091,69€, pois o número de admissões desta HAI é 
baixo, a sua severidade alta e, consequentemente, consumiu mais recursos. Em contrapartida a BSI foi 
a HAI mais barata, com um custo médio por admissão de 2151,31€. 
Este estudo foi o primeiro que usou dados nacionais e técnicas inovadoras para estimar os DALY e os 
custos das HAI em Portugal. Comparando com outros estudos na Europa o número de DALY por 
admissão é maior em Portugal Continental. Não obstante, este número está alinhado com as evidências 
do Centro Europeu para a Prevenção e Controlo de Doenças (ECDC, European Centre for Disease 
Prevention and Control) onde Portugal apresenta uma das maiores taxas de HAI na União Europeia e 
na Área Económica Europeia (EU/EEA). Quando comparamos os custos médios com outros países 
como França, Reino Unido ou EUA, os custos destes países são mais baixos, porque a incidência de 
HAI em Portugal é maior do que nos outros países. 
Este estudo é retrospetivo e exploratório, ou seja, é suportado pela informação respetiva ao ano de 2016 
apresentando os primeiros resultados nacionais relativos às seis HAI do ponto de vista dos DALY e dos 
custos, sendo um ponto de partida para outros estudos/análises. 
Relativamente à base de dados utilizada, não estamos a considerar casos clínicos, mas casos 
administrativos e como tal vai depender dos médicos codificadores de cada hospital, havendo assim 
casos em que ocorre sobrevalorização ou subvalorização das admissões com registo de infeção. 
 Estes resultados são alarmantes e mostram que é necessário reunir esforços para reforçar as políticas de 
saúde nesta área. No entanto, esta análise é conservadora e espera-se que a carga total das HAI seja 
maior, tanto clínica como economicamente. Não obstante, dá-nos um alerta para os custos excessivos 
com as HAI tornando necessário que a redução destes seja uma prioridade.  
 
 
Palavras-chave: Doenças Infecciosas, Infeção Associada aos Cuidados de Saúde, DALY, Carga da 
Doença, Custo Ajustado 
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Chapter 1: Introduction 
 
Epidemics of infectious diseases (ID) have been documented throughout history. In ancient Greece and 
Egypt there were descriptions of epidemics of smallpox, leprosy, tuberculosis, meningococcal 
infections, and diphtheria [7].  
The morbidity and mortality of infectious diseases profoundly shaped politics, commerce, and culture. 
Theories about ID have evolved in different timings according to our understanding of the world, 
sometimes slowly, sometimes with incredible speed [8]. 
For example, the bubonic plague and its coinfections, measles and smallpox, were the most devastating 
of the epidemic diseases. In 166 BC the Roman Empire was ravaged by the Antonine Plague (165-180 
BC), which likely killed both co-emperors Lucius Verus (130 – 169 BC) and Marcus Aurelius (121 -
180 BC) along with 5 million others [9,10]. Between 1104 and 1110 nearly 90% of Europeans were 
killed by plague [11].The plague, also known as the Great Plague or Black Death struck again in 1345 
and swept across Europe, then spread to Egypt in 1347 on merchant ships carrying rats and fleas infected 
with the plague bacillus, Yersinia pestis [7]. Until 1351, the Black Death killed 24 million Europeans (3 
out of 10) and 40 million deaths worldwide [7,12–14]. These waves of bubonic plague fundamentally 
affected the development of civilizations as well as imposed a genetic bottleneck on those populations 
exposed to the viruses [8]. 
Smallpox, on the other hand, was disseminated during the Arabian expansion, the Crusades, the 
discovery of the West Indies, and the colonization of the Americas. This disease was brought to the New 
World by Spanish and Portuguese conquerors and the mortality rates were between 60-90%. Smallpox 
travelled across the Americas, devastating the previously unexposed American populations [15]. 
Syphilis is another epidemic ID of great historical importance. Syphilis became epidemic in the 1490s 
as a highly contagious venereal disease in Spain, Italy, and France. By 1530, the venereal spread of 
syphilis was widely recognized in Europe [16]. 
In Western medicine, Hippocrates (460-377 BC) was among the first to record his theories on the 
occurrence of disease. In his treatise Airs, Water and Places, Hippocrates dismissed supernatural 
explanations of diseases and instead attributed illness to characteristics of the climate, soil, water, way 
of life, and nutrition surrounding the patient [17–20]. It is Hippocrates who invented the terms endemic 
and epidemic disease to differentiate those diseases that are always present in population, endemic, from 
those that are not always but sometimes occurred in large numbers, epidemic [8]. 
The fact that IDs were contagious was recognized in early epidemics, but because knowledge of the true 
epidemiology of diseases was lacking, efforts to control the spread of such diseases were flawed. Plague 
was recognized to be contagious; however, the control measures focused primarily on quarantine and 
disposal of the bodies and the possessions of the victims [8]. 
Fracastoro (1478-1553) in his published book (1546), De contajione, ontagiosis morbis et curatine (On 
Contagion, Contagious Diseases, and their Treatment), proposed the revolutionary theory that infectious 
diseases were transmitted from person to person by minute invisible particles [12,21]. He formulated 
the idea that infections were spread from person to person by minute invisible seeds, or seminaria, that 
were self-replicating, and acted on the humours of the body to create disease. [8]. Fracastoro postulated 
that the environment become polluted with seminaria and that epidemics occurred in association with 
certain atmospheric and astrologic conditions [12,21]. He proposed three modes of transmission of 
contagious diseases: by direct contact from one person to another, through contact with fomites (a term 
for contaminated articles still used today), and through the air [8]. 
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Based on the observation that smallpox disease conferred immunity in those who survived, intentional 
inoculation of healthy people to induce immunity was attempted. This process was known as variolation 
and was advocated by Thomas Jefferson (1743-1826), Benjamin Franklin (1706-1790) and Cotton 
Mather (1663-1728). In 1796, Edward Jenner (1749-1823), based on the observation that milkmaids 
were immune to smallpox, greatly improved the process by substituting cowpox in place of the human 
pathogen. He performed the first vaccine trial on a child with lesions containing cowpox (vaccinia virus) 
and later showed that the boy was immune to variolation, or challenge with variola virus [22]. 
Thomas Sydenham (1624-1689) focused on the individual and their illness rather than on trying to 
differentiate a specific disease. After Sydenham, the Italian physician Giovanni Morgagni (1682-1771) 
inaugurated the method of clinicopathologic correlation. This new way of thinking about diseases, 
requiring careful clinical observation, differentiation, and specific diagnosis, led naturally to the search 
for specific, as opposed to general, causes of illness [8]. 
Expanding the concept of careful clinical observation of individuals, epidemiologists in the 1800s 
observed unusual epidemics and performed controlled studies to exposed persons. Epidemiologic 
theories about the means of transmission of various infectious diseases often preceded the laboratory 
and clinical studies of the causative organisms [8]. 
The epidemiology of bacterial diseases also progressed at this time. Ignatz Semmelweiss (1818-1865) 
demonstrated with a retrospective record review that an epidemic of puerperal fever, or childbed fever, 
in 1847 at the Vienna lying hospital was due to transmission of infection on the hands of medical 
students and physicians who went from the autopsy room to the delivery room without washing their 
hands. In contrast, the women who were delivered by midwives, who used aseptic techniques (by 
immersing their hands in aseptic solution prior to contact with the patient), had much lower rates of 
puerperal sepsis [23] (Figure 1.1).  
 
 
Figure 1.1 - Mortality rates in first and second divisions (wards) of the Department of Obstetrics in the Vienna Lying-In Hospital 
between 1839 and 1849 [8]. 
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In the area of statistics, Gerolamo Cardana (1501-1576) introduced the concept of probability and 
described that the probability of any roll of the dice was equal as long as the die was fair [8]. This 
concept was carried further by Jacques Bernoulli (1654-1705) with the central limit theorem which 
states that the observed probability approached the theoretical one as the number of observations 
increased [8]. John Graunt (1620-1674) detailed the number and causes of deaths in London during the 
preceding third of a century. He used inductive reasoning to interpret the mortality trends and noted the 
ratio of male to female births and deaths, mortality by season, and mortality in persons living in rural 
versus urban locations. He examined several causes of deaths over time and constructed the first life 
table [24]. Chadwick (1800-1890) used health statistics to effectively change public policy. His report 
“to the Poor Law Commission” (1842) outlined the cost effectiveness of public health. It emphasized 
the understanding that hygiene was closely related to health, but he also linked mortality to hygiene and 
health [8]. 
Anton van Leeuwenhoek (1632-1723) was the first to observe microorganisms describing how materials 
such as rainwater and human excretions had cocci, bacilli and spirochetes (bacteria) [11]. Louis Pasteur 
(1822-1895) demonstrated the dependence of fermentation on microorganisms, in 1857, and showed 
that these organisms came from similar organisms present in the air [25]. And finally, Robert Koch 
(1843-1910) proposed the “Henle-Koch postulates” to prove that a microorganism was the cause of an 
infection disease [8].  
To study a disease in a controlled setting, some researches resorted to self-experimentations. Angelo 
Dubini (1813-1902) intentionally exposed his skin to a hookworm inoculum and was unable to find the 
organism on his exposed skin. After several experiments, he reported the entrance of hookworms into 
humans by skin penetration of the parasites, rather than by ingestion [8]. Other example is the explosive 
epidemic nature of yellow fever and malaria when they occurred in Europe and United States. Stubbins 
Firth (1784-1820) realised a series of self-experiments, and unable to transmit the infection in these 
experiments concluded that yellow fever was not directly transmitted from person to person [12]. In 
1889, Walter Reed (1851-1902) and a yellow fever commission were able to report that the disease was 
transmitted to humans by the bite of an infected mosquito after several definitive experiments [26]. 
Later, Reed and his colleagues demonstrated that the causative agent of yellow fever was present in 
filtered blood leading them to concluded that the causative agent of yellow fever was a virus [26]. This 
conclusion made yellow fever the first identified viral cause of human disease [8]. 
In the 1930s and 1940s, Alexander Fleming, Howard Florey and Ernst Chain conducted experiments 
that led to the demonstration that penicillin, a mould product, was effective against many pathogenic 
organisms [27]. Penicillin was shown to be effective against syphilis, gonorrhoea and pneumococcal 
infections [8]. In 1931, Germany scientists at Bayer explored the antibacterial effects of dyes, combining 
sulphanilamide with a dye produced antibacterial drug (Prontosil). After Florey and Chain published a 
paper describing a purification technique, penicillin became available in the market (limited) in 1945 
[28] with the help of interested drug companies [29]. With the success of penicillin, the race to produce 
other antibiotics began [29] and the following next years became the “Golden Age” of antibiotic 
discovery [28].  
The success and results of antibiotics were impressive, but at the same time a problem called antibiotic 
resistance has appeared. This is a problem that surfaced not long after the introduction of penicillin and 
threatens the usefulness of these important medicines [29]. 
Almost from the beginning, doctors noted that in some cases, penicillin was not useful against certain 
strains of Staphylococcus aureus (bacteria that causes skin infections). Since then, this problem of 
resistance has grown worse, involving other bacteria and antibiotics [29].  
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Since the “Golden Age” of antibiotics, the discovery of new classes of antibiotics has been almost non-
existent, as showed in Figure 1.2. It represents a situation that is especially problematic considering the 
resiliency of bacteria shown over time and the continued misuse and overuse of antibiotics in treatments 
[30]. Consequently, some serious infectious have become more difficult to treat, forcing doctors to 
prescribe a second or even third antibiotic when the first treatment does not work [29]. 
 
 
                                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 - Timeline of antibiotic resistance compared to antibiotic development. [94] 
5 
 
In light of this growing antibiotic resistance, many doctors have become much more careful in the way 
they prescribe these medicines. In the USA, doctors lowered the numbers of antibiotic prescriptions they 
prescribed for children with common respiratory infections by about 40% during the 1990s [29].  
During the XX century, the average life span of persons in the USA (for example) lengthened by about 
30 years, where 25 years of this gain has been attributed to advances in public health. The public health 
actions to control infectious diseases in the 1900s, included marked improvements in sanitation, water 
chlorination of nearly all public water supplies, development and use of vaccines to prevent infectious 
diseases and antibiotics for their treatment, along with improved methods for diagnosis [8] (Figure 1.3). 
 
 
 
Regarding healthcare-associated infections (HAIs), it was with Ignatz Semmelweiss that the first HAI) 
was documented demonstrating that IDs could be acquired in medical facilities, i.e., IDs were not 
acquired only in the community, but also in the facilities where these infections should be healed [31]. 
HAIs are infections that patients get while receiving treatment for medical or surgical conditions. Each 
year millions of people acquire a HAI in hospitals of UE and USA (Figures 1.4-1.6), that are responsible 
for thousands of deaths and costs millions to the states [2–4]. It is evident that this is a problem for 
public health and for the healthcare systems of the different countries, especially because most of these 
HAIs are preventable. So, to help in the war against the problem a HAI surveillance must be done.  
Figure 1.3- Crude death rate due to infectious disease, United States, 1990-1996 [8] 
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Figure 1.5 - Percentage of Staphylococcus aureus isolates resistant to meticillin (MRSA) in HAIs in acute care 
hospitals, ECDC PPS 2011-2012. *Country representativeness of the PPS data was optimal or good in 25 (76%) 
countries, and poor or very poor in 8 (24%) countries. Countries (number of participating hospitals) with poor 
representativeness were: Austria (n=9), Croatia (n=11), Czech Republic (n=14), Estonia (n=4), Norway (n=7), 
Romania (n=10) and countries with very poor representativeness were Denmark (n=3) and Sweden (n=4) and 
are indicated by a “*” in maps and tables  [95]. 
Figure 1.4- Distribution of HAI types by presence of HAI on admission in acute care 
hospitals, ECDC PPS 2011-2012.  [5] 
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To have an idea of the impact of these infections it is necessary study their “burden of disease”. “Burden 
of disease” is the study of the impact of a disease(s) in a population or a geographical area, using a 
multitude of indicators: number of infections, deaths, associated deficiencies, years of life lost, quality 
of life, costs, etc.  
Figure 1.6 - Observed HAI prevalence with 95% confidence intervals and predicted HAI prevalence based on case mix 
and hospital characteristics, by country, ECDC PPS 2011–2012. *Country representativeness of the PPS data was optimal 
or good in 25 (76%) countries, and poor or very poor in 8 (24%) countries. Countries (number of participating hospitals) 
with poor representativeness were: Austria (n=9), Croatia (n=11), Czech Republic (n=14), Estonia (n=4), Norway (n=7), 
Romania (n=10) and countries with very poor representativeness were Denmark (n=3) and Sweden (n=4). Denmark: upper 
limit of 95% confidence interval not included HAI prevalence=9.8% (95% CI 1.0– 52.7)  [5]. 
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As previously described, Portugal has serious problems with HAIs. How to measure their impact? In 
Portugal, there are only a few studies of this type [32–34], so a further progress of the quantification of 
the burden of HAIs in Mainland Portugal is of crucial importance to the citizens, the national healthcare 
system (SNS, Sistema Nacional de Saúde) and the Infection Prevention and Control area (IPC). 
In this work the impact of six specific infections were studied and two indicators, disability-adjusted life 
years (DALYs) and costs, were used to estimate the burden of disease.  
The HAIs studied were the six most common, namely: healthcare-associated pneumonia (P), healthcare-
associated primary bloodstream infection (BSI), healthcare-associated C. difficile infection (CDI), 
healthcare-associated urinary tract infection (UTI), healthcare-associated surgical side infection (SSI) 
and healthcare-associated neonatal sepsis (Neo).  
DALYs are a health gap measure that combines both time lost due to premature mortality and to non-
fatal conditions. They are calculated as the sum of years of life lost (YLLs) due to premature mortality 
and years lost due to disability (YLDs) [32]. The use of DALYs provides a common metric to aid 
meaningful comparison of the burden of risk factors, diseases, and injuries [35]. HAI costs will help 
understand the impact for each admission with HAI, and alert healthcare system responsible of excessive 
costs.  
This is a retrospective and exploratory work, which means that it is supported by the information of the 
past year of 2016, presenting the first national results about the six HAIs from the point of view of 
DALYs and costs, as a starting point for further analyses.  
The thesis is organized as follows: Chapter 2 presents the study of the impact evaluation of these six 
infections using the DALY indicator. This work followed Cassini et al, 2016 [1] approach to the  burden 
of disease of the most common six HAIs. This study is presented in a format of a working paper 
submitted to “The Journal of Hospital Infection”, preceded by an introduction. Chapter 3 evaluates the 
impact of the HAIs costs indicator through a working paper to be submitted to “Acta Médica 
Portuguesa”. It will end with chapter 4 where the results obtained in the previous chapters and some 
considerations are presented. 
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Chapter 2: The Burden of Disease of some relevant Healthcare-
Associated Infections in Portugal: results of a national exploratory 
study based on administrative hospital datasets 
 
In this chapter the burden of disease of some relevant infections in Portugal (Mainland) with support of 
the literature will be discussed. It is based on Cassini et al. [1] article that approaches the burden of 
disease of six HAIs on the European population, using the DALY methodology. It used the 2011/12 
data from the European Centre for Disease Prevention and Control (ECDC) point prevalence survey 
(PPS) of HAIs and antimicrobial use in European acute care hospitals to estimate the burden of six 
common HAIs. These HAIs are healthcare-associated pneumonia (P), healthcare-associated primary 
bloodstream infection (BSI), healthcare-associated C. difficile infection (CDI), healthcare-associated 
urinary tract infection (UTI), healthcare-associated surgical side infection (SSI) and healthcare-
associated neonatal sepsis (Neo).  
Cassini et al. [1] concluded that the cumulative burden of the six HAI cited above was higher than the 
total burden of all other 32 communicable diseases included in the Burden of Communicable Diseases 
in Europe (BCoDE) 2009-2013 study and the model used should allow for the estimation of the potential 
benefit of preventive measures on the burden of HAIs in the European Union and European Economic 
Area (EU/EEA). 
DALYs are a health gap measure that combines both time lost due to premature mortality and to non- 
fatal conditions. They are calculated as the sum of years of life lost (YLLs) due to premature mortality 
and years lost due to disability (YLDs) [30]. 
For an easier understanding of the working paper, the calculation of the DALY for the CDI will be given 
as an example. 
In order to calculate DALY, the formula is: 
𝐷𝐴𝐿𝑌 = 𝑌𝐿𝐿 + 𝑌𝐿𝐷  (2.1) 
 
with: 
𝑌𝐿𝐿 =  ∑ 𝐷(𝑖) × 𝐿(𝑖)
𝑛
𝑖=0
 (2.2) 
 
 and, 
𝑌𝐿𝐷 = ∑ 𝐼(𝑖) × 𝐷𝑊 × 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐷𝑖𝑠𝑎𝑏𝑖𝑙𝑖𝑡𝑦 
𝑛
𝑖=0
  
(2.3) 
 
 
 
 
Where, D(i) is the number of people that died at age i, L(i) is the standard loss function specifying years 
of life lost for a death age i and I is the incidence at age i (i.e. the number of cases of an infection at age 
i). DW (disability weight for the condition) and Average Duration of Disability (in years) can be found 
in the outcome trees of Cassini et al. study [1,36]. The age i varies between 0 and 101 years.  
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Figure 2.1- Decision tree for CDI [36] 
It will be considered that CDI has uncomplicated and complicated cases. The percentage of 
uncomplicated cases (Unc.) lies between [85-98.5%] and the complicated between [1.5-15%]. So for 
the uncomplicated cases a percentage of 98.5% was considered, according to Cassini et al. [1], and by 
complementarity complicated cases had 1.5%. So, starting by the uncomplicated cases we will consider 
the follow tree (Figure 2.2):   
        Figure 2.2- Decision tree of uncomplicated CDI [36] 
The probability of the other branches will be the same for both cases. It will be considered the highest 
probability for death (D) and post-colectomy state (PC), P(D|Unc.)= 0.11 and P(PC|Unc.)=0.038, 
according to Cassini et al. [1]. This means that the P(R|Unc.) = 1-0.11-0.038 = 0.852. Using the 
incidence at age 0 (Table 2.1) we will have: 
 
𝑈𝑛𝑐. (0)  = 𝐼(0)  ×  𝑃(𝑈𝑛𝑐. )  =  0.474 ×  0.985 =  0.467 𝑢𝑛𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑒𝑑 𝑝𝑒𝑜𝑝𝑙𝑒   
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with,  
 
𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 (0) =
𝑁𝐶(0)
∑ 𝑁𝐶(𝑖)108𝑖=0
× 321 = 0.474  𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝐶𝐷𝐼  
(2.4) 
 
 In (2.4) 321 is the estimated number of cases with CDI in our universe of 11,467 admissions with 
infection based on the PPS 2017 of ECDC where it was estimated that in 2016, in Portugal, that 43 
patients had CDI out of a total of 21,339 patients per day. 
 
        Table 2.1- Incidence of CDI by age. 
 
 
 
  
 
Now, to calculate the number of people in the recovered, death and post-colectomy state at age 0: 
𝑅 (0) =  𝑈𝑛𝑐. (0) ×  P(R|Unc. ) = 0.467 × 0.852 =  0.398 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑝𝑒𝑜𝑝𝑙𝑒   
  
  
𝐷 (0) =  U𝑛𝑐. (0) ×  P(D|Unc. ) = 0.467 × 0.11 =  0.051 𝑑𝑒𝑎𝑡ℎ 𝑝𝑒𝑜𝑝𝑙𝑒    
𝑃𝐶 (0) =  U𝑛𝑐. (0) ×  P(𝑃𝐶|Unc. ) = 0.467 ×  0.038  =  0.017 𝑝𝑜𝑠 − 𝑐𝑜𝑙𝑒𝑐𝑡𝑒𝑚 𝑠𝑡𝑎𝑡𝑒 𝑝𝑒𝑜𝑝𝑙𝑒   
Secondly, YLL will be calculated, by the formula (2.2) for age 0: 
𝑌𝐿𝐿 (0)  =  𝐷(0) ×  𝐿(0) =  0.051 × 80.78 =  4.147 𝑦𝑒𝑎𝑟𝑠 𝑜𝑓 𝑙𝑖𝑓𝑒 𝑙𝑜𝑠𝑡      
For the calculation of YLD (expression 2.3), recovered people and PC people are the only ones 
considered. For DW the highest value in the range or the exact value given in Figure 2.2, 0.149 and 
0.125 respectively are used. For the Average the highest value in range (0.0219 years) is also used or 
when it says, “Rem. Life Exp.” (remaining life expectancy the standard loss function, L(i) is used. So, 
for age 0: 
𝑌𝐿𝐷𝑅(0) = 𝐼(0) × 𝐷𝑊 × 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 = 0.474 × 0.149 × 0.0219 = 0.0015 𝑦𝑒𝑎𝑟𝑠  
𝑌𝐿𝐷𝑃𝐶(0) =  𝐼(0) × 𝐷𝑊 × 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 = 0.474 × 0.125 × 80.78 = 4.784 𝑦𝑒𝑎𝑟𝑠  
𝑌𝐿𝐷𝑇𝑜𝑡𝑎𝑙(0) = 𝑌𝐿𝐷𝑅(0) + 𝑌𝐿𝐷𝑃𝐶(0) = 0.0015 + 4.784 = 4.786 𝑦𝑒𝑎𝑟𝑠  
Now, with YLL and YLD calculated, 
𝐷𝐴𝐿𝑌𝑈𝑛𝑐.(0) = 𝑌𝐿𝐷𝑇𝑜𝑡𝑎𝑙(0) + 𝑌𝐿𝐿𝑈𝑛𝑐.(0) = 4.786 + 4.147 = 8.933 𝑦𝑒𝑎𝑟𝑠  
 
Repeating analogous calculations for each age and summing up at the end the total DALY for the 
uncomplicated cases is obtained:  
Age No of cases (NC) Incidence (I) 
0 2 0.474 
2 1 0.237 
4 3 0.711 
5 1 0.237 
… … … 
101 1 0.237 
Total 1355 321 
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𝐷𝐴𝐿𝑌𝑈𝑛𝑐. =∑𝐷𝐴𝐿𝑌𝑈𝑛𝑐.(𝑖)
𝑛
𝑖=0
 
 
 
For the complicated cases, to calculate 𝐷𝐴𝐿𝑌𝐶𝑜𝑚𝑝., the process is analogue: 
𝐷𝐴𝐿𝑌𝐶𝑜𝑚𝑝. =∑𝐷𝐴𝐿𝑌𝐶𝑜𝑚𝑝.(𝑖)
𝑛
𝑖=0
 
 
 
Finally, for the CDI DALY, we will have:  
𝐷𝐴𝐿𝑌 = 𝐷𝐴𝐿𝑌𝑈𝑛𝑐. + 𝐷𝐴𝐿𝑌𝐶𝑜𝑚𝑝. = 1529.98 𝑦𝑒𝑎𝑟𝑠 
 
 
 
2.1 Working Paper I, submitted to “The Journal of Hospital Infection” 
 
The Burden of Disease of some relevant Healthcare-Associated Infections in 
Portugal: results of a national exploratory study based on administrative 
hospital datasets 
Tremoceiro P1, Tavares DP2, Barão, MI1 
1- FCUL, Campo Grande, 1749-016, Lisboa 
2-Egas Moniz-Cooperativa de Ensino Superior, CRL Campus Universitário Quinta da Granja-Monte de 
Caparica 2829-511, Caparica 
Summary 
Objectives This study aims to estimate the burden of disease of the six most common healthcare-
associated infections observed in Mainland Portugal in 2016 using administrative hospital datasets. 
Methods The relevant cases for this study were obtained using the National Hospital Morbidity 
Database, which contains the admissions records for 2016 corrected by data from the European Centre 
for Disease Prevention and Control (ECDC) Point Prevalence Study. In order to measure the burden of 
disease the number of disability-adjusted life years (DALY) was chosen as the most appropriate metric. 
To calculate the DALYs components the weights defined by the literature on outcome trees for six 
healthcare-associated infections (HAIs) and the standardised life expectancy of National Statistics 
Institute mortality table 2015-2017 were considered. 
Findings In 2016, 11,467 cases of HAIs were estimated. Healthcare-associated urinary tract infection 
(UTI) and healthcare-associated pneumonia (P) were the infections with the highest number of cases, 
32.09% and 24.87%, respectively. The age group [80-108] was the one with the highest rate of HAIs 
(40.19% of all admissions). The average age of the patients was 68.70 years old with a standard deviation 
of 34.78 years. The infection with the highest DALY per admission was the healthcare-associated 
bloodstream infection (BSI) with 13.43 DALYs. UTI had 39,322 DALYs which represents 33.64% of 
the total DALYs and is also the infection with the largest DALY per 100,000 inhabitants (4,448 per 
100,000). 
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Conclusions This is the first study that uses national data to estimate the burden of HAIs in Portugal. 
UTI and Pneumonia are the infections with the highest weight in Mainland Portugal and should be the 
priority in the war against HAIs and its impacts. The surgical site infection (SSI) has the lowest number 
of DALYs mainly due to the fact that the majority of SSI infections (when they occur) do not imply an 
admission in the hospital, only severe SSI would have been registered in the database used in the study. 
The number of DALYs per admission with infection estimated in this work is higher than the DALYs 
calculated by other studies in Europe. Nonetheless, this increased level is aligned with the ECDC 
evidence where Portugal has one of the highest rates of HAIs in the European Union and European 
Economic Area (EU/EEA). 
 
Introduction  
The term burden of disease refers to a quantitative estimation of the impact of a disease on a population 
or geographical region, using a multitude of indicators [37]. Estimation of the burden of disease 
expressed in disability-adjusted life years (DALYs) is a comprehensive and evidence-based approach 
to evaluate the burden of a disease that can be used to inform policy making in public health [1]. DALY 
is a composite measure that accounts not only for the mortality data but also includes short-term and 
long-term disabilities that result from the disease [1]. DALYs provide a standard metric to aid 
meaningful comparison of the burden of risk factors, diseases, and injuries [35]. It is also intended to 
promote an evidence-based approach to assess population health and foster analysis of surveillance data 
quality and availability. It facilitates the communication of complex health information to decision- 
makers and provides a tool for the planning and prioritisation of infectious disease prevention, 
preparedness and control measures [38].  
In order to help the promotion of an evidence-based approach to assess population health, the Institute 
for Health Metrics and Evaluation (IHME) in collaboration with World Health Organization (WHO) 
develops in a regular basis the Global Burden of Disease Study (GBD) [39]. In its last edition in 2017, 
by decreasing order, that ischemic heart disease, neonatal disorders, stroke, lower respiratory infections 
and diarrhoea were the health problems that accounted for more years of life lost (YLL) in the world. 
Low back pain, headache disorders depressive disorders are the ones who accounted for more years lost 
due to disability (YLD) worldwide. In Portugal, the estimates pointed out, that stroke, ischemic heart 
disease, lung cancer and Alzheimer’s disease accounted  for more YLL, and low back pain, diabetes, 
headache disorders and depressive disorders accounted for more YLD [40]. 
In Portugal, there are a few studies using DALYs [32–34], besides the study published in 2018 by the 
National Directorate of Health [41], which conclude that in 2016, the leading causes of early death 
(YLLs) were ischemic heart disease, stroke, Alzheimer’s disease and lung cancer.  
These “top four” health problems are the same that appeared in the year of 2017 [40] only with a different 
leading order, ischemic heart disease in 2016 and one year later stroke. In 2016, the leading causes of 
disability (YLDs) were low back and neck pain, sense organ diseases, depressive disorders and migraine, 
by descending order. Comparing with the data of the IHME website [40] in 2017, low back pain (with 
more YLDs) and depressive disorders continue on the “top” leading YLDs, along with two new health 
problems: diabetes and headache disorders. 
According to some estimates from the GDB project, IDs (infectious diseases) represent less than 10% 
of the total burden of disease in Europe [42,43]. There are some difficulties in estimating the burden of 
IDs for the fact that they occur on very different time scales [44], the relationships with later chronic 
sequelae are not clearly established [45], infections do not only lead to acute illness but might also result 
in chronic and long-term sequelae, requiring the use of an incidence- and pathogen- based DALY 
approach [37,44], and the difficulty to attribute morbidity to a specific pathogen. This incidence and 
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pathogenic-based approach furthermore allows a proper prediction of potential effects of interventions 
aiming at preventing infections, which is the primary focus in decision making [37].  
Even though the recognition by the scientific community of the importance of the Burden of Disease 
studies in the Infection Prevention and Control (IPC) area, it is only possible to refer, to our knowledge, 
two studies that use the DALY metric in IPC: the study of the Burden of Six Healthcare-Associated 
Infections on European Population Health [1] and the Attributable deaths and disability-adjusted life-
years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area 
in 2015 [46].  
The first one [1] refers that a significant proportion of HAIs are preventable, and they are considered to 
be a marker of patient care quality. In this study DALYs were calculated to estimate the burden of 
disease of six HAIs and the need for increased efforts for the prevention and control of the HAIs was 
concluded. 
The second one [46] aimed to estimate the burden of five type of infections caused by antibiotic-resistant 
bacteria of public health concern in countries of the EU and EEA in 2015, qualified by the number of 
cases, attributable deaths and DALYs. It concluded that the estimated burden of antibiotic-resistant 
bacteria in EU and EEA was substantial compared to other infectious diseases and provided useful 
information for public health decision-makers prioritising interventions for infectious diseases.  
By giving information through DALYs it will be possible to leapfrog the Portuguese National Health 
System (SNS, Sistema Nacional de Saúde) into another level and promote with an evidence-based 
approach the infectious disease prevention and control strategies. Furthermore, it can also help improve 
prioritising and planning public health system [38], like the Slovenian national estimation of the burden 
of tick-borne encephalitis did with the  identification of age groups with the highest DALYs in order to 
develop more efficient vaccination strategies [47]. 
Taking into account the gap in Portugal in using DALY for the IPC area, this study aims to characterise 
the burden of disease of the HAIs in Mainland Portugal and also to compare the results with the ones 
obtained when the incidence-based DALY methodology using the mindset of Cassini et al. [1] is used. 
 
Methods  
To ensure that the previous objectives are achieved, a non-clinical retrospective transversal study was 
designed, based on HAIs, where increased morbidity, mortality and excess costs are included [1]. The 
HAIs considered in this study are six, the same considered by Cassini et al in their study [1], i.e.: 
healthcare-associated urinary tract infection (UTI), healthcare-associated primary bloodstream infection 
(BSI), healthcare-associated neonatal sepsis (Neo), healthcare-associated C. difficile infection (CDI), 
surgical site infection (SSI), and healthcare-associated pneumonia (P). 
For this study, incidence data from the National Hospital Morbidity Database provided by the 
Administração Central do Sistema de Saúde, IP (ACSS) was used regarding the inpatient records of 
2016 in Mainland Portugal and the records with, at least, one diagnosis of infection coded by ICD-9-
CM were selected. Table 1-A (in the annexs) shows the codes considered per studied infection [48–55]. 
It is important to refer that if more than one diagnosis was coded for the same type of infection, the 
infection was counted just one time. On the other hand, if in the same episode, more than one diagnosis 
was coded for different types of infection it was considered that the patient would have more than one 
infection. 
After the selection of the six infections total cases (159,305 cases with HAIs and non-HAIs; 9.75% of 
the total records) to achieve the primary goal of the study, i.e., to assess the impact of HAIs, the incidence 
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of the infections of interest was corrected using the data from the Point Prevalence Study 2017 of ECDC 
[56], because the data from the National Morbidity Database used in this study contained patients with 
HAIs and non-HAIs. Then this prevalence was annualised and its percentage was considered according 
to the total of infections. The number of HAIs was estimated as 11,467 (0.7% of the total). 
The number of years of life lost due to premature mortality (YLLs) was calculated compared to a 
standardized life expectancy [57] (in this case the mortality table of Portugal from 2015-2017, for both 
genders, was used, provided by INE [58]). 
Considering that the DALY (YLL+YLD) is a composite health measure estimating not only the number 
of years of life lost due to premature mortality (YLL), but also the number of years lived with disabilities 
(YLD). The number of YLDs in the study population was calculated using the following formula [59]: 
 
𝑌𝐿𝐷 =  𝐼 ×  𝐷𝑊 ×  𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑖𝑠𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (in years)     
 
In the above expression, I is the incidence of the infection (i.e. the number of admissions with diagnosis 
of infection in the total number of admissions [60]), DW is the disability weight for the condition used 
by Cassini et al [1] (i.e., the ‘valuation’ of time lived in non-fatal health states formalises and quantifies 
the loss of health for different states of health [59]), corrected with a multiplicative model due to multiple 
disabilities, specially at elderly age [19] and the Average Duration of the disability (in years) can be 
found in the outcome trees of Cassini et al. study [36] (the maximum value of the average duration was 
used for the calculations). 
 
Results 
During 2016, there occurred 1,632,375 hospital admission, in Mainland Portugal. To achieve the goals 
of this study, 159,304 records (9.75%) were selected using the codes of infection previously mentioned 
which corresponds to patients diagnosed with, at least, one of the infections studied for research. 
Considering that the data on the National Morbidity Database cannot distinguish patients with HAIs and 
non-HAIs, after the previously mentioned correction, the number of cases in the study was 11,467 (0.7% 
of the total). 
The distribution of cases by HAI and by age group is represented in Fig. 2.3, where Urinary Tract 
Infections (UTI) and Pneumonia (P) are the infections with the more cases, 32.09% and 24.87%, 
respectively. Clostridium difficile infection (CDI) is the one with fewer cases (2.80%), not considering 
sepsis neonatal (Neo) because it only affects children with less than one year old. The age group of [80-
108] is the one that has the highest incidence (not considering Neo) with 40.19% of the total infections.  
Analysing the most incident infection per age group, for the [0,17] group, the most incident infection is 
Neo with a weight of 31.05 %. In the age-groups [18,49] and [50,64] the HAI with more weight is SSI 
with incidence of 46.58% and 40.30%, respectively. For groups [65,79] and [80,108] years, UTI is the 
HAI with more cases 31.60% and 39.15%, respectively.  
The number of admissions increases with age, especially from [50,64] to [65,79] and then, again, from 
[65,79] to [80,108]. The number of infections between 18 and 49 years old represents 8.50% of the total 
admissions in that group age, and the number of infections in the age group of [80,108] only represents 
6.48% of the admissions, the lowest percentage. 
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Table 2.2 - The Estimated annual burden of the six healthcare-associated infections, Mainland Portugal, 2016.  
*Null standard deviation (patients are 0 years old). 
The estimated burden of the six selected type of HAIs is presented in Table 2.2. UTI is the HAI with 
higher incidence (33.64%). The average age in this infection is 72.92 years. CDI has an average age of 
74.67 years (the highest average age) while SSI has an average age of 61.77 years (the lowest average 
age).  
According to the data, HAIs accounted for 116,907 DALYs in Mainland Portugal in 2016 (YLLs 
accounted for 10.80% and YLDs for 89.20% of the total). 
 
Healthcare-Associated Infection 
No of HAIs 
cases estimated 
for 2016 
Average age 
± Standard 
deviation 
(years) 
YLL YLD 
Total of 
DALYs 
Clostridium difficile infection 
(CDI) 
321 74.67 ± 34.85 467 1,063 1,530 
Surgical Site Infection (SSI) 2,792 61.77 ± 31.73 1,019 14 1,033 
Bloodstream infection (BSI) 1,613 72.11 ± 36.38 5,021 16,643 21,664 
Neonatal Sepsis (Neo) 209 0.00* 2,364 19,572 22,116 
Pneumonia (P) 2,852 72.47 ± 36.5 1,545 29,697 31,242 
Urinary Tract Infection (UTI) 3,680 72.92 ± 36.78 2,207 37,115 39,322 
Overall 11,467 68.7 ± 34.78 12,623 104,284 116,907 
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Figure 2.3 - Number of cases by age group of the six healthcare-associated infections (HAIs) considering the total admissions 
by HAI, Mainland Portugal, 2016 
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When comparing the HAIs by the number of DALYs per admission with infection a total of 40.21 
DALYs per admission in the public hospitals of Mainland Portugal (Fig. 2.4) was estimated. It is 
possible to mention that the HAI with more DALYs per admission is the BSI (13.43 DALYs; 33.41%) 
and SSI is the hospital-acquired infection with fewer DALYs per admission (0.37 DALYs; 0.88%), Neo 
is not presented in the figure, but each admission with Neo infection accounts for more than 80 DALYs 
per case. 
 Figure 2.5 - Number of DALYs of incidence of the six healthcare-associated infections (HAIs) per 100,000 inhabitants,      
Mainland Portugal, 2016 
HAIs accounted for 13,225 DALYs per 100,000 general population. As shown in Fig. 2.5, The HAI 
with more DALYs per 100,000 general population is UTI with 4,448 per 100,000. CDI and SSI are the 
infections with the lowest number of DALYs per 100,000 general population with 173 per 100,000 and 
117 per 100,000, respectively. 
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Figure 2.4- Number of DALYs per admission with, at least, one of the six healthcare-associated infections (HAIs), Mainland 
Portugal, 2016. 
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Discussion  
Using the mentioned scientific approach, the burden of HAI expressed in DALYs for the whole 
Mainland Portugal was estimated which provides the possibility to identify public health threats and 
ways to improve health based on evidence [61] and a possible answer to essential goals of WHO defined 
by the AMR and HAIs Health Burden Estimation working group [62]. 
For our best knowledge, this is the first study in Portugal which addresses the topic using the country as 
a whole, and that led to refer that all age groups are affected by the HAIs, and their burden is significantly 
higher in children until 17 years old, 34.84% (considering Neo). Without considering Neo the burden in 
this age group reduces substantially to 15.92% and the new age group with higher burden is the one with 
elderly between 65 and 79 years. The age group with the lowest burden of disease is the one that includes 
adults between 80 and 108 years old (12.24%). Being this the first national study, it becomes more 
difficult to compare the observed results by age group with other national statistics or results.  
 Contrarily to Cassini et al.’s study [1] where Pneumonia is the HAI with the highest-burden (33.70%) 
and the first in rank of DALYs per 100,000 population, in this study the HAI with the highest burden of 
disease was the UTI (33.64%) and only in the second place, Pneumonia represented 26.72% of the total 
burden of HAIs under study and is the second in raking of DALYS per 100,000 population. Despite the 
disagreement with Cassini et al.’s results, the estimated burden of UTIs for Portugal agrees with Otter’s 
publication about HAIs and its burden [6] which puts the UTI on the top of the HAIs which causes more 
DALYs in the real world. 
Considering that DALYs promotes the idea of priority in public health [61], it is very interesting to refer 
that most of the results of this study follow Otter’s range of importance for HAIs in the real world [6]. 
In this study, the number of DALYs per admission with infection is higher than the one obtained by 
Cassini et al.’s study for all EU/EEA countries, because as ECDC evidenced, [5,56], [63] Portugal 
presents one of the highest rates of HAIs and given that for Cassini et al. study [1] data of all EU was 
estimated, this increment would be expectable for Portugal (the global tax in Europe in 2016/2017 was 
6.50%, in Portugal was 9.10% and in 2011/2012 in Europe was 5.70% and in Portugal 10.80%).  
Surgical site hospital-acquired infections (SSI) have the lowest number of DALYS mainly due to the 
fact that the majority of SSI infections when they occur do not imply an admission in the hospital and 
based on that only severe SSI would have be registered in the database used in the study. Besides this 
limitation, the result of a low weight of YLD (1.36%) and a high weight of YLL (98.64%) for SSIs is 
coincident with Cassini et al. study [1]. 
Bloodstream infections (BSI) have the highest number of DALYs per admission unlike what happens 
per 100,000 inhabitants, because the quotient between the total number of BSI DALYs and the number 
of admissions is not proportional to the quotient of the total number of BSI DALYs and the number of 
inhabitants. This means that the number of inhabitants is higher than the number of BSI admissions and 
leads to different results. 
Comparing with Cassini et al. [1], the number of total DALYs is 116,907 for the 883,952 people 
considered in this study of Mainland Portugal (13,225 DALYs per 100,000 population), and is much 
more significant than the EU/EEA in the same year (501 DALYs per 100,000 general population). This 
fact can occur by three motives: first, the limitation of not having the number of HAIs directly; second, 
the infection rate in Portugal is higher than that of EU/EEA; third, this study uses the total Portuguese 
population, while in Cassini et al. a sample of the hospitals patients in EU/EEA was used (in some more 
prominent countries only few hospitals were counted [56],[63]. 
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Considering the number of admissions with registered infection, this number can be underrated because 
of the methodology used to report the codification of the infections and, consequently, it depends on the 
codifier and the hospital.  
There are other limitations that need to be addressed: the outcome trees used were built on available 
published evidence, and the resulting disease progression pathway may not always entirely reflect the 
definition of a case of HAI, but they were the best available approximation, as Cassini et al. [1] explained 
and only six types of HAIs were studied and may lead to an underestimation of the total burden of HAIs 
in Portugal. 
Besides these limitations, this is an innovative study using for the first time data at national level which 
estimates the healthcare-associated infections DALYs and provides ways to address this public health 
challenge and implement directional strategies which can be more productive and reduce the future cost 
of HAIs in Portugal. 
For future work, taking into account the Friedrich study [64], DALYs will be calculated at regional level 
because regional and local dynamics can influence some results in public health, specially the HAIs 
ones and also a suggestion to Administração Central do Sistema de Saúde, IP will be sent to include a 
variable on the National Morbidity Database that accounts for HAIs or non-HAIs for each infection 
diagnosis. 
 
Conclusions 
This is the first study that estimates the burden of disease for HAIs in Mainland Portugal at national 
level. Using DALY it was possible to estimate that during 2016 there were 11,467 cases of HAIs in 
Mainland Portugal which caused 116,907 disability-adjusted life years. 
BSI, Pneumonia and UTI were three of the HAIs with higher burden of disease (apart from Neo) which 
corresponded to 13.43, 10.95 and 10.69 DALYs per admission with infection. These alarming results 
show that it is necessary to take a path of efforts to reinforce the health politics in this area. 
The results of this work are mostly aligned with other studies’ results, adjusted by the reality in Portugal, 
a country with one of the highest infection rates in the EU/EEA area. 
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Chapter 3: Tastings and flavours about costs of Healthcare-
Associated Infections in Portugal: an insight using administrative 
hospital data 
 
In this chapter, the costs of the healthcare-associated infections in Mainland Portugal and their impact 
on the Portuguese National Health System (SNS, Sistema Nacional de Saúde) will be analysed.  
The Diagnostic Related Groups (DRG) constitute a classification system of inpatients in hospitals that 
group the patients in clinically coherent and similar groups from the point of view of the consumption 
of resources. It operationally defines the products of an hospital, set of goods and services that each 
patient receives according to his needs and pathology that leads him to the hospitalization and part of 
the defined treatment process [65]. 
Length of stay (LOS) is the used total number of days by each inpatient in the multiple services of a 
health establishment in a reference period, except the discharge day from that health establishment [66].   
The DRG price involves all provided services during the hospitalisation, whether in the hospital ward 
or in intensive care units, including all medical care, complementary diagnostic and therapeutic means, 
as well as hospitality [66]. 
For each episode there can only correspond one DRG, from the admission date until the discharge date, 
regardless of the number of services in which the patient has been treated [66].  
The episodes of admission classified in DRG can be normal/typical or exceptional (short duration or 
prolonged evolution) in function of the time variable of LOS. Normal or typical episodes present longer  
LOS than the inferior threshold (minimum number of days in the estimated range of length of stay 
considered by Portuguese Hospital Morbidity Database) and shorter LOS than the superior threshold 
(maximum number of days in the estimated range of length of stay considered by Portuguese Hospital 
Morbidity Database). Short duration episodes present the admission time equal or inferior to the inferior 
threshold of DRG in what they were classified. Prolonged evolution episodes show admission time equal 
or superior to the high threshold of the DRG respective. Typical/normal and prolonged evolution 
episodes correspond to 1 equivalent patient (Eqv.). Short duration episodes correspond to less than 1 
equivalent patient, 𝐸𝑞𝑣 =
 𝐿𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑠𝑡𝑎𝑦 
𝐿𝑜𝑤𝑒𝑟 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑
  [66]. 
Inpatients with less than a 24-hour stay, who get out of the hospital against doctor orders or who die are 
considered as short duration patients. Inpatients with less than a 24 hours, transferred to another health 
establishment are not considered as equivalent patients [66].  
If a patient stays in the health establishment less than 24 hours, even if he stays during the night, his/her 
episode is paid as an ambulatory episode (medical or surgical). The concept of DGR of ambulatory 
applies only to the programmed admissions, whether in surgical activity or in medical activity. 
Ambulatory surgery is a programmed surgery that is realised as an outpatient care service with a 
recovery period less than 24 hours even though it is effectuated in an inpatient facility effectuated in 
hospitalisation regime. The base price for programmed admissions, medical and surgical ambulatory is 
2,285€ [66]. 
In this exploratory work the LOS was not considered in the costs, because in spite of it is needed for the 
calculations of the equivalent patients, these values were already presented in the Portuguese Hospital 
Morbidity Database [66].  
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Tastings and flavours about costs of Healthcare-Associated Infections in 
Portugal: an insight using administrative hospital data 
Tremoceiro P1, Tavares DP2, Barão, MI1 
1- FCUL, Campo Grande, 1749-016, Lisboa 
2-Egas Moniz-Cooperativa de Ensino Superior, CRL Campus Universitário Quinta da Granja-Monte de 
Caparica 2829-511, Caparica 
Summary 
Objectives This study aims to fill the that exists in Portuguese literature on healthcare-associated 
infections (HAIs) costs and to alert healthcare system responsible of excessive costs.  
Methods The relevant cases for this study were estimated using the National Hospital Morbidity 
Database which contains the admissions records for 2016 corrected by the data from the European 
Centre for Disease Prevention and Control (ECDC) Point Prevalence Study. To calculate the inpatient 
cost the rule defined for 2016 ACSS’s circular invoice was considered and then it was divided by the 
number of infections to determine the adjusted cost. To estimate the average cost for HAI per 100 
admissions and per age group averages based on the weight of APR31 severity levels that are mentioned 
on the ACSS database were calculated. 
Findings In 2016, 11,467 cases of HAIs were estimated. Urinary tract infection (UTI) was the HAI with 
the highest number of infections, 32.09%. This HAI is also the most expensive in Mainland Portugal 
corresponding to 10.93€ million, while clostridium difficile (CDI) is the cheapest, 0.79€ million. 
Considering the average cost by admission with HAI, neonatal sepsis costs 4,091.69€ being the most 
expensive.   
Conclusions This is the first study that uses national data to estimate the costs of HAIs in Portugal. UTI 
was the most expensive HAI and Neo had the major costs per admission. Bloodstream infection (BSI) 
had the lowest cost per admission due to individuals that die before they reach the minimum expected 
number of inpatient or the individuals can have other infections affecting the average costs calculations. 
The average costs in Portugal are different than other countries, because the prevalence of HAIs in 
Portugal is higher than those countries. The total costs of this HAIs round the 33€ million and their 
reduce need to be a priority for the portuguese healthcare responsible. 
 
Introduction 
Healthcare-associated infections (HAIs) are related with increased morbidity and mortality and excess 
costs, and because a significant proportion of them are preventable, they are considered to be a marker 
of quality of patient care [67]. 
Considering the existence of interventions described in the literature that can substantially reduce the 
incidence of HAIs, [68] and of analyses indicating that at least 50% of them are preventable [69,70], it 
urges to study why, e.g., in the USA, roughly 1.7 million hospital-associated infections occur annually 
in acute-care hospitals [4] and why HAI costs approximately 7€ billion in Europe [3].  
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In Portugal, studies that estimates extra costs of around 10,000€ per patient with one  central line-
associated bloodstream infection (CLABSI) [71] and a total cost of 407,999,814€ for five HAIs in 
Centro Hospitalar Universitário de Lisboa Central (CHULC) [72] were published. Associating these 
results with those of the European Centre for Disease Prevention and Control (ECDC) of 2012 and 2017, 
where Portugal is very bad positioned [5,63], the need of more studies in this area is enhanced.  
Despite an public health mandate to minimize the occurrence and impact of HAIs, identifying the most 
cost-effective or even effective strategies to do so is a source of uncertainty [73]. A number of strategies 
have been proposed, ranging from environmental controls and modifications to the education of patients 
and health care providers on hand hygiene [73]. Invariably, hand hygiene is a part of any effort to control 
HAIs [73], however, despite the availability of solutions, the strong ethical case for improvement, and 
the intuitive argument that saving lives ought to save money, large-scale progress against HAIs has been 
slow. Only recently have health care organizations begun to achieve successes and overcome doubts 
about the scalability of pilot studies [74]. 
It is well known that elderly people are more vulnerable for the acquisition of infections than younger 
population and have higher mortality and morbidity rates due to infections [75]. According to some 
studies [75–77], elderly individuals are at higher risk of developing HAIs, possibly in part of the 
immunosenescence, [75] and have statistical higher mortality rates than the rest of the patients (with 
HAIs) [78,79]. Besides this, mortality rates are higher in patients that developed HAIs than patients who 
did not, both in elderly and non-elderly groups [80,81]. 
The inappropriate use of antibiotics contributes to antimicrobial-resistant bacteria in hospitals and in the 
community [2,82]. Dealing with Antimicrobial Resistance (AMR) complications could cost up to USD 
3.5 billion a year on average across the 33 countries included in the OECD analysis [82]. Between 2015-
2050, Italy, Greece and Portugal are forecasted to top the list of OECD countries with the highest 
mortality rates from AMR [82].  
Besides the AMR/HAIs problem in Portugal, there is a lack of Portuguese literature on the issue of  HAIs 
costs, where only local studies were possible to find [71,72]. 
This study aims to fill this gap, by being the first at national level which estimates the costs associated 
with the most significant and targetable HAIs in the country. By attesting the existence and magnitude 
of such consequences, an important step is taken in order to help the definition and adoption of the best 
prevention campaigns and/or alternative payment systems [72]. 
 
Methods 
To ensure that the previous objectives are achieved, a study was designed based on Chapter 2, using the 
same data but with the goal to study the costs of those inpatient records. 
The HAIs considered in this study are the following: urinary tract infection (UTI), primary bloodstream 
infection (BSI), neonatal sepsis (Neo), Clostridium difficile infection (CDI), surgical site infection (SSI), 
and pneumonia (P). 
For this study data from the National Hospital Morbidity Database provided by the Administração 
Central do Sistema de Saúde, IP (ACSS) was used, regarding the inpatient records of 2016 in Mainland 
Portugal. 
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During 2016, 1,632,375 inpatient records were observed. Using Chapter’s 2 methodology only 159,304 
cases with at least one diagnosis of infection were selected, which included cases of HAIs and non-
HAIs. 
To estimate the cost of each admission the rule defined for 2016 ACSS’s circular invoice [66] was 
considered, which calculate the cost of an inpatient record i, i=1,…,159,304, as the result of the 
following formula: 
 𝐶𝑜𝑠𝑡 𝑜𝑓 𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑖 =  2,285 × 𝑅𝑊𝑖  × 𝐸𝑞𝑣𝑖  
where 2,285€ is the Portuguese standard price for all Diagnostic Related Groups (DRG), 𝑅𝑊𝑖 is the 
relative weight for  𝐷𝑅𝐺𝑖 and 𝐸𝑞𝑣𝑖 corresponds to the number of equivalent patients relative to the 
 𝐷𝑅𝐺𝑖.  
 RW represents the quantity of resources that was used for each admission, where the standard weight 
is 1 and is comprehended in [0, +ꝏ [. Regarding the number of equivalent patients it is [66].: 
𝐸𝑞𝑣𝑖 =
{
 
 
 
 
𝐿𝑂𝑆𝑖
𝐿𝐿𝐷𝑅𝐺𝑖
 (< 1), 𝑖𝑓                       𝐿𝑂𝑆𝑖 < 𝐿𝐿𝐷𝑅𝐺𝑖  
1, 𝑖𝑓                           𝐿𝐿𝐷𝑅𝐺𝑖 < 𝐿𝑂𝑆𝑖 < 𝑈𝐿𝐷𝑅𝐺𝑖
1, 𝑖𝑓                                             𝐿𝑂𝑆𝑖 > 𝑈𝐿𝐷𝑅𝐺𝑖
 
Where, 𝐿𝐿𝐷𝑅𝐺𝑖 is lower length and 𝑈𝐿𝐷𝑅𝐺𝑖 is upper length. 
Taking into account that there is the possibility to have in one admission i more than one infection, the 
calculated cost was adjusted by the number of infections of the admission: 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐶𝑜𝑠𝑡𝑖 =
  𝐶𝑜𝑠𝑡 𝑜𝑓 𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑖
𝑁º 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑖
 
 
 
where the cost of admission and the number of infections corresponds to the admission i=1,…,159,304. 
Due to the fact that the scope of the paper is only related with HAIs, the number of cases included 
dropped to 11,467 after correction for the incidence of each HAI [56]: 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐶𝑜𝑠𝑡𝑖,𝑗 =
  𝐶𝑜𝑠𝑡 𝑜𝑓 𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑖
𝑁º 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑖
 ×  𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐻𝐴𝐼  𝑖,𝑗 
 
 
where the cost of admission and the number of infections is related with admission i=1,…,11,467 and 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐻𝐴𝐼𝑖,𝑗 corresponds to the percentage of 𝐻𝐴𝐼 𝑗in the admission i of a patient with an infection 
j=1,…,6. 
𝑊𝑒𝑖𝑔ℎ𝑡 𝐻𝐴𝐼𝑖,𝑗 = {
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐻𝐴𝐼𝑗, 𝑖𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑖 ℎ𝑎𝑠 𝐻𝐴𝐼𝑗
0,                                     𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
                       𝐻𝐴𝐼𝑗 =
{
 
 
 
 
1,   𝑖𝑓 𝐻𝐴𝐼 = 𝐶𝐷𝐼
2,   𝑖𝑓 𝐻𝐴𝐼 = 𝑆𝑆𝐼
3,   𝑖𝑓 𝐻𝐴𝐼 = 𝐵𝑆𝐼
4,   𝑖𝑓 𝐻𝐴𝐼 = 𝑁𝑒𝑜
5,   𝑖𝑓 𝐻𝐴𝐼 =    𝑃  
6,   𝑖𝑓 𝐻𝐴𝐼 = 𝑈𝑇𝐼
 
To estimate the average cost for HAI per admission averages based on the weight of APR31 (All Patient 
Refined, DRG version 31) severity levels that are mentioned on the ACSS database were calculated. 
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For the average cost adjusted by HAI we have: 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑐𝑜𝑠𝑡𝑖 = 
∑ 𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐶𝑜𝑠𝑡𝑖,𝑗𝑗
𝑁𝑜 𝑜𝑓 𝐻𝐴𝐼𝑖
      (3.1) 
 
where the costs and admissions is related with infection i=1,…,11,467. 
The result of (3.1) was corrected taking into account the weight of the HAIs in the total infections, 
according to Chapter 2. 
To use and extract data from the National Database of Hospital Morbidity in this study the computer 
program IBM SPSS Statistics 25 was used. 
 
Results 
The distribution of cases by HAI and by age group is represented in Fig. 3.1, where Pneumonia (P) and 
Urinary Tract Infections (UTI) are the infections with the most cases, 24.87% and 32.09%, respectively. 
Clostridium difficile infection (CDI) is the one with less cases (2.80%), not considering sepsis neonatal 
(Neo) because it only affects children with less than 1 year old. The age group of [80,108] is the one 
that has the higher incidence (not considering Neo) with 40.19% of the total infections.  
Analysing the most incident infection per age group, for [0,17] years the most incident infection is Neo 
with a weight of 31.05 %. In the age’s group [18,49] and [50,64] years groups the HAI with more weight 
is SSI with incidences of 46.58% and 40.30%, respectively. Between [65,79] and [80,108] years, UTI 
is the HAI with more cases, 31.60% and 39.15%, respectively.  
The number of admissions increases in all age groups, especially from [50,64] to [65,79] and then, again, 
from [65,79] to [80,108]. The number of infections between 18 and 49 years old represents 8.50% of 
the total admissions in that group age and the number of infections in the age group of [80,108] only 
represents 6.48% of the admissions, the lowest percentage. 
 
 Figure 3.1- Number of cases by age group of the six healthcare-associated infections (HAIs) considering the total admissions 
by HAI, Mainland Portugal, 2016 
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Regarding the total adjusted cost in function of age group by HAI, the age group of [80,108] is the most 
expensive, 12,109,066.94€ (36.68%). The age group of [0,17] is the one with less costs (7.12%). 
Fig. 3.2 presents the total adjusted cost by HAI, where UTI is the most expansive infection (10.93€ 
million), while CDI is the cheapest (0.79€ million).  
         Figure 3.2- Total adjusted cost by admission with HAI, Mainland Portugal, 2016 
 
 Fig. 3.3 shows the total average adjusted cost by admission, where Neo is the most expensive, 4091.69€, 
while BSI is the cheapest, 2151.31€.  
    Figure 3.3- Average adjusted cost by admission with HAI, Mainland Portugal, 2016 
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Discussion 
In Portugal, in 2016, the six HAIs in study had a total estimated cost of 33,010,424.88€. CDI was the 
cheapest HAI with a cost of 788,733.01€, and UTI the most expensive one, corresponding to 
10,933,738.33€. The age group of [0,17] had lowest costs (7.12%) and the age group of [80,108] had 
the highest costs (36.68%). Considering the average cost by admission with HAI, BSI had the lowest 
cost of 2,151.31€ and Neo the highest, 4,091.69€.   
The fact that bloodstream infection is the HAI with the lowest total average adjusted cost per admission 
(2,151.31€) can occur due to two reasons. This serious infection can have a very high number of deaths 
[83–86] and, consequently, the individuals die before they reach the minimum expected number of 
inpatient (3.55%), or the individuals with BSI can also have other infections (70.23%) and in the 
calculations of the average cost, this cost was divided by the number of infections and, possibly, turned 
out a lower value than expected. 
On the other hand, Neo is a HAI with one of the lowest total cost, but according to Fig. 3.3 it is the most 
expensive per admission with HAI. This can be explained by the lower number of admissions with this 
HAI (209 admissions), the high severity of the HAI and, consequently, consuming more resources [87]. 
The average cost of UTI in Portugal was 2,971.12€, a way more than in the USA, $896 to $1006 
(≈802.17€ to 900.65€) [88]. The average cost of CDI by admission is 2,457.11€ a way less than the cost 
by case in the USA of $11,285 (≈10,103.18€) [74]. For BSI the average cost by admission is 2,151.31€, 
which is low cost comparing to the USA average cost, $1,822 to $110,800 (≈1631.19€ to 99,196.47€) 
[88]. In this study, SSI has an average cost by admission of 3,033.60€ and in the USA these infections 
are responsible for a cost of $20,875 (≈18,688.87€) per admission [74]. 
This difference between the costs of the HAIs in Portugal and in other countries, like United States, 
comes from the fact that the incidence of HAIs in Portugal  is lower than in the other countries [74]. It 
can exist an underrated incidence in Portugal, because diagnostic data was used and no data was 
collected especially for this study. 
This study has some limitations to consider, like the fact that the data relative to the costs of the 
infections in study covers the HAIs and non-HAIs, where there is no discrimination between the two 
groups and we needed to using the number of HAIs of Chapter 2. This leads to consider the same costs 
for HAIs and non-HAIs [89]. 
Other important concepts to ponder when determining the attributable costs of HAIs are comorbidity 
conditions, as well as length of stay (LOS) in the hospital prior to acquiring the infection [90]. 
Considering this as the first national study about HAIs’ costs using the comorbidities and LOS would 
leave no room for other publications in the field, which seem to be of extreme importance. So, those 
will be considered in future papers. Nonetheless, it is recognised that without an adjustment for 
comorbidities or LOS can result in more expensive HAIs [91]. 
Other interesting aspect to contemplate and, also a future line of investigation, is the fact that the problem 
of HAIs is related with the problem of AMR. With an increase in the prevalence of resistant organisms 
and incentives to discharge patients quickly while minimizing readmission rates, concerns about HAIs 
will likely be higher [73]. 
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Conclusions 
This study will help reinforce the literature about the costs of HAIs in Portugal, in other to give more 
clarification to the community, specially to the scientific community. This study is also an innovator 
one, because is the first to use national data of all the public hospitals in Portugal Mainland to estimate 
the costs of HAIs.  
UTI is the most expensive HAI in Portugal Mainland (considering the total costs), 10.93€ million and 
CDI is the cheapest, 0.79€ million, but per admission Neo is the most expensive, costing 4091.69€ to 
Portuguese national healthcare system (SNS, Sistema Nacional de Saúde). BSI only costs 2,151.31€ due 
to individuals that die before they reach the minimum expected number of inpatient or the individuals 
can have other infections affecting the average costs calculations.  
The results of this study are estimated costs and must be careful analysed, because this work is of 
explorative nature, nonetheless representing a country. These costs are a starting point for further 
analyses but can nonetheless give an alert of excessive costs to the healthcare system responsible.   
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Chapter 4: Conclusion 
 
The aim of the present study was to estimate the national healthcare burden associated with HAIs, in 
Mainland Portugal, during a 1-year time horizon. 
Through this work it is possible to characterize the burden of disease of the most frequent six HAIs, in 
Portugal Mainland, in 2016. It was concluded that occur 11,467 cases of these six HAIs with a 
correspondent 116,907 DALYs. UTI was the most incident HAI corresponding to 39,322 DALYs with 
an average age of 72.92 years and SSI was the HAI with less incidence, 1,033 DALYs, and 61.77 years 
old of average age. BSI was the HAI with the higher burden, 13.43 DALYs per admission with infection. 
SSI is again, the HAI with less DALYs per admission with infection, 0.37 DALYs.  
Analysing the costs of the HAIs (33,010,424.88€), the age group of [0-17] was the cheapest (7.12% of 
the total costs) and the age group of [80-108] the most expensive (36.68% of the costs). UTI was the 
HAI with major total costs, 10.93€ million and Neo was the most expensive HAI per admission with 
infection, 4091.69€. Portugal had a higher incidence of HAIs than other countries and because of this it 
had higher costs than these countries.  
Results are significant and in line with literature, adjusted by the reality in Portugal, a country with one 
of the highest infection rates in the EU/EEA area. 
The present study has quantified the substantial socio-economic burden that HAIs place on the 
healthcare system in Portugal to be of 116,907 DALYs and 33,010,424,88€ per year. These results are 
alarming and show that is necessary to undertake efforts to reinforce health politics in this area. 
However, our analysis was conservative and the total burden is expected to be greater, both clinically 
and economically. This study is the first at a national level presenting the results about six of the most 
common HAIs from the point of view of DALYs and costs, but can also be starting point for further 
analyses. Nonetheless it gives an alert for the excessive expense with HAIs, making its reduction a 
priority. 
DALYs have also some limitations. Being a measure of mortality and health status, this measure cannot 
include considerations of pain and discomfort, nor of the broader demands of caring and nursing which 
accompany some conditions of ill-health. It is also an effectiveness measure, depending on assessing 
outcome, not considering the situation of deprivation. The discounting life is also a problem, according 
to the philosophic optic, especially for people with life-long disabilities because their lives should be 
valued equally to those of people with no disabilities. It is considered a form of discrimination against 
people with disabilities [92]. But despite of these critics, DALYs give very good information about 
health state of the patients, informing when to act and where the resources needed to be relocated. It is 
a very good indicator for the burden of disease. DALYs can be complemented with patient-reported 
outcome measures (PROM) that are questionnaires completed by patients to measure their perception 
of their functional well-being and health status, questionnaires EQ-5D and SF-36, for instance [93]. 
Findings (confirming expectation of high values of DALYs and costs associated to these infections) 
have important policy implications such as decision of investing in prevention campaigns and other 
infection control interventions to reduce HAIs incidence. In this model, HAI incidence could be varied 
to examine the clinical and economic impact of its reduction.  
The bespoke health economic model developed for this analysis, based on these data, may be a valuable 
tool for future clinical and economic evaluations of infection control strategies in Portugal. 
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Annex I 
Table A- ICD-9 codes 
HAI ICD-9 
code 
Code description  
C. difficile 
infection (CDI) 
008.45 Intestinal infection due a C. difficile 
 
 
 
 
 
 
 
 
Urinary tract 
infection (UTI) 
590.1 Acute pyelonephritis  
590.10 Acute pyelonephritis without lesion of renal medullary necrosis   
590.11 Acute pyelonephritis with lesion of renal medullary necrosis   
590.2 Renal and perinephric abscess 
590.3 Pyeloureteritis cystica  
590.8 Other pyelonephritis or pyonephrosis, not specified as acute or 
chronic 
590.80 Pyelonephritis, unspecified  
590.81 Pyelitis or pyelonephritis in diseases classified elsewhere  
595.0 Acute cystitis  
595.89 Other specified types of cystitis  
595.9 Cystitis, unspecified  
597.80 Urethritis, unspecified  
599.0 Urinary tract infection, unspecified  
771.82 Urinary tract infection of newborn 
996.64 Due to indwelling urinary catheter  
 
 
 
 
 
 
 
 
Pneumonia (P) 
 
 
 
 
 
 
 
 
 
 
 
 
 
480.0 Pneumonia due to adenovirus 
480.1 Pneumonia due to respiratory syncytial virus 
480.2 Pneumonia due to parainfluenza virus 
480.3 Pneumonia due to SARS- associated virus  
480.8 Pneumonia due to other viruses not elsewhere classified  
480.9 Viral pneumonia unspecified  
481 Pneumococcal pneumonia/ streptococcus pneumoniae 
pneumonia 
482.0 Pneumonia due to Klebsiella pneumoniae 
482.1 Pneumonia due to Pseudomonas 
482.2 Pneumonia due to Hemophilus influenza; H. influenzae 
482.3 Pneumonia due to streptococcus 
482.30 Pneumonia due to streptococcus; streptococcus unspecified 
482.31 Pneumonia due to streptococcus; group A 
482.32 Pneumonia due to streptococcus; group B 
482.39 Pneumonia due to streptococcus; other streptococcus 
482.4 Pneumonia due to staphylococcus 
482.40 Pneumonia due to staphylococcus, unspecified 
482.41 Methicillin susceptible pneumonia due to staphylococcus 
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Pneumonia (P) 
482.42 Methicillin resistant pneumonia due to staphylococcus 
482.49 Other staphylococcus pneumonia 
482.8 Pneumonia due to other specified bacteria 
482.81 Pneumonia due to other specified bacteria; anaerobes 
482.82 Pneumonia due to other specified bacteria; Escherichia coli 
482.83 Pneumonia due to other specified bacteria; other gram-negative 
bacteria 
482.84 Pneumonia due to other specified bacteria; legionnaires’ disease 
482.89 Pneumonia due to other specified bacteria; other specified 
bacteria 
482.9 Bacterial pneumonia unspecified 
483.0 Pneumonia due to other specified organism; mycoplasma 
pneumoniae 
483.1 Pneumonia due to other specified organism; chlamydia 
483.8 Pneumonia due to other specified organism; other specified 
organism 
484.1 Pneumonia in cytomegalic inclusion disease 
484.3 Pneumonia in whooping cough 
484.5 Pneumonia in anthrax 
484.6 Pneumonia in aspergillosis 
484.7 Pneumonia in other systemic mycoses 
484.8 Pneumonia in other infectious diseases classified elsewhere 
485 Pneumonia, organism unspecified 
486 Bronchopneumonia, organism unspecified 
487.0 Influenza with pneumonia 
997.31 Pneumonia associated to a ventilator  
Neonatal sepsis 
(Neo) 
771.81 Sepsis of newborn  
 
 
 
Bloodstream 
infection (BSI) 
995.91 Sepsis 
995.92 Severe sepsis  
999.31 Infection due to central venous catheter  
999.32 Bloodstream infection due to central venous catheter  
999.33 Local infection due to central venous catheter 
038.9 Unspecified septicemia 
 
 
 
 
Surgical side 
infection (SSI) 
 
 
 
 
 
 
 
 
 
 
324.1 Intraspinal abscess 
478.24 Retropharyngeal abscess (after cervical surgery) 
513.1 Abscess od mediastinum 
519.2 Mediastinitis  
567.2 Other suppurative peritonitis  
567.21 Peritonitis (acute) generalized  
567.22 Peritonietal abscess 
567.29 Other suppurative peritonitis  
567.38 Other retroperitoneal abscess 
567.39 Other retroperitoneal infections 
567.81 Choleperitonitis 
567.89 Other specified peritonitis 
567.9 Unspecified peritonitis 
569.61 Colostomy infection  
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Surgical side 
infection (SSI) 
614.3 Acute parametritis and pelvic cellulitis  
674.30 Other complications of obstetrical surgical wounds  
674.32 Other complications of obstetrical surgical wounds, delivered, 
with mention of postpartum complication 
674.34 Other complications of obstetrical surgical wounds, postpartum 
condition or complication 
682.1 Neck cellulitis and abscess, other 
682.2 Trunk cellulitis and abscess, other   
682.6 Cellulitis and abscess of leg except foot  
686.00 Pyoderma, unspecified  
686.09 Other pyoderma  
686.1 Pyogenic granuloma of skin and subcutaneous tissue  
686.8 Other specified local infections of skin and subcutaneous tissue  
686.9 Unspecified local infection of skin and subcutaneous tissue  
711.06 Pyogenic arthritis, lower leg  
711.66 Arthropathy associated with mycoses, lower leg 
711.96 Unspecified infective arthritis, lower leg  
730.06 Acute osteomyelitis, lower leg 
730.08 Acute osteomyelitis, other specified sites  
730.26 Unspecified osteomyelitis, lower leg   
730.28 Osteomyelitis with or without mention of periostitis, other 
specified sites 
730.96 Unspecified infection of bone, lower leg  
875.1 Open wound of chest (wall) 
996.60 Reaction-unspecified device/graft 
996.61 Due to cardiac device, implant and graft 
996.62 Due to vascular device, implant and graft 
996.63 Due to nervous system device, implant and graft 
996.67 Due to other internal orthopedic device, implant and graft 
996.69 Due to other internal prosthetic device, implant, and graft 
997.09 Surgical complication nervous system NEC 
998.31 Disruption-internal operative wound 
998.32 Disruption-external operative wound 
998.51 Infected postoperative seroma 
998.59 Other postoperative infection (abscess)  
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